Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer

British Journal of Cancer

Volumn 88, Issue 12, 2003, Pages 1894-1899

  Uenishi, T ^a   Kubo, S ^a   Hirohashi, K ^a   Tanaka, H ^a   Shuto, T ^a   Yamamoto, T ^a   Nishiguchi, S ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CYFRA 21 1; Intrahepatic cholangiocarcinoma; Primary liver carcinoma; Tumour marker

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BLOOD LEVEL; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER INVASION; CHEMOLUMINESCENCE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; KRUSKAL WALLIS TEST; LIVER CANCER; LIVER DISEASE; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; RANK SUM TEST; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTIGENS, NEOPLASM; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; HUMANS; KERATINS; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0037478838     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601026     Document Type: Article

References (58)

1. Balaton AJ, Nehama-Sibony M, Gotheil C, Callard P, Baviera EE (1988) Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections. J Pathol 156: 305-310
2. Bergquist A, Glaumann H, Persson B, Broome U (1998) Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 27: 311-316
3. Brechot JM, Chevret S, Nataf J, Le Gall C, Fretault J, Rochemaure J, Chastang C (1997) Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 33: 385-391
4. Brockmann JG, St Nottberg H, Glodny B, Heinecke A, Senninger NJ (2000) CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res 6: 4249-4252
5. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, Hoen H (2000) Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 31: 7-11
6. Chu KM, Lai EC, Al-Hadeedi S, Arcilla Jr CE, Lo CM, Liu CL, Fan ST, Wong J (1997) Intrahepatic cholangiocarcinoma. World J Surg 21: 301-306
7. Curley SA, Izzo F, Gallipoli A, De Bellis M, Cremona F, Parisi V (1995) Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer. Ann Surg 222: 375-383
8. Dohmoto K, Hojo S, Fujita J, Yang Y, Ueda Y, Bandoh S, Yamaji Y, Ohtsuki Y, Dobashi N, Ishida T, Takahara J (2001) The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines. Int J Cancer 91: 468-473
9. Doweck I, Barak M, Uri N, Greenberg E (2000) The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer 83: 1696-1701
10. Gaarenstroom KN, Bonfrer JM, Kenter GG, Korse CM, Hart AA, Trimbos JB, Helmerhorst TJ (1995) Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Cancer 76: 807-813
11. Harrison LE, Fong Y, Klimstra DS, Zee SY, Blumgart LH (1998) Surgical treatment of 32 patients with peripheral intrahepatic cholangiocarcinoma. Br J Surg 85: 1068-1070
12. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M (1993) A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18: 147-153
13. Inoue K, Makuuchi M, Takayama T, Torzilli G, Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Konishi M, Kinoshita T, Miyagawa S, Kawasaki S (2000) Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 127: 498-505
14. Johnson DE, Herndier BG, Medeiros LJ, Warnke RA, Rouse RV (1988) The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma. Am J Surg Pathol 12: 187-197
15. Kashihara T, Ohki A, Kobayashi T, Sato T, Nishizawa H, Ogawa K, Tako H, Kawakami F, Tsuji M, Tamaoka K (1998) Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level. J Gastroenterol 33: 447-453
16. Kawaguchi H, Ohno S, Miyazaki M, Hashimoto K, Egashira A, Saeki H, Watanabe M, Sugimachi K (2000) CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer 89: 1413-1417
17. Kawarada Y, Mizumoto R (1984) Cholangiocellular carcinoma of the liver. Am J Surg 147: 354-359
18. Kawarada Y, Mizumoto R (1990) Diagnosis and treatment of cholangiocellular carcinoma of the liver. Hepatogastroenterology 37: 176-181
19. Kim HJ, Yun SS, Jung KH, Kwun WH, Choi JH (1999) Intrahepatic cholangiocarcinoma in Korea. J Hep Bil Pancr Surg 6: 142-148
20. Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y, Arase Y, Murashima N, Chayama K, Kumada H (2000) Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer 88: 2471-2477
21. Kubo S, Kinoshita H, Hirohashi K, Hamba H (1995) Hepatolithiasis associated with cholangiocarcinoma. World J Surg 19: 637-641
22. Lai RS, Hsu HK, Lu JY, Ger LP, Lai NS (1996) CYFRA 21-1 enzyme-linked immunosorbent assay: evaluation as a tumor marker in non-small cell lung cancer. Chest 109: 995-1000
23. Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, Chen TJ, Pao CC (1986) Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis: a prospective study. Gastroenterology 90: 263-267
24. Madariaga JR, Iwatsuki S, Todo S, Lee RG, Irish W, Starzl TE (1998) Liver resection for hilar and peripheral cholangiocarcinoma: a study of 62 cases. Ann Surg 227: 70-79
25. Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M (1995) Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol 26: 956-964
26. Metz CE, Herman BA, Roe CA (1998a) Statistical comparison of two ROC-curve estimates obtained from partially-paired datasets. Med Decis Making 18: 110-121
27. Metz CE, Herman BA, Shen JH (1998b) Maximum likelihood estimation of receiver operating characteristic (ROC) curves from continuously-distributed data. Stat Med 17: 1033-1053
28. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R (1992) The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31: 11-24
29. Nakamura S, Suzuki S, Sakaguchi T, Serizawa A, Konno H, Baba S, Muro H (1996) Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma. Cancer 78: 1671-1676
30. Nakata B, Chung Ys, Kato Y, Ogawa M, Ogawa Y, Inui A, Maeda K, Sawada T, Sowa M (1996) Clinical significance of serum CYFRA 21-1 in gastric cancer. Br J Cancer 73: 1529-1532
31. Nakata B, Ogawa Y, Ishikawa T, Ikeda K, Kato Y, Nishino H, Hirakawa K (2000) Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 89: 1285-1290
32. Nichols JC, Gores GJ, Larusso NF, Wiesner RH, Nagorney DM, Ritts Jr RE (1993) Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 68: 874-879
33. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S (1995) Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346: 1051-1055
34. Nisman B, Lafair J, Heching N, Lyass O, Baras M, Pretz T, Barak V (1998) Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer 82: 1850-1859
35. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S (1994) Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 19: 61-66
36. Osborn M, Van Lessen G, Weber K, Kloppel G, Altmannsberger M (1986) Different diagnosis of gastrointestinal carcinoma by using monoclonal antibodies specific for individual keratin polypeptides. Lab Invest 55: 497-504
37. Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18-29
38. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB (1993) Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometrlc assay as a marker of lung cancer. Cancer Res 53: 61-66
39. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R (1995) Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 108: 865-869
40. Sanchez-Carbayo M, Espasa A, Chinchilla V, Herrero E, Megias J, Mira A, Soria F (1999) New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem 45: 1944-1953
41. Shin HR, Lee CU, Park HJ, Seol SY, Chung JM, Choi HC, Ahn YO, Shigematsu T (1996) Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 25: 933-940
42. Sobin LH, Wittekind CH (1997) TNM Classification of Malignant Tumours, 5th edn. New York: Wiley-Liss
43. Sorensen HT, Friis S, Olsen JH, Thulstrup AM, Mellemkjaer L, Linet M, Trichopoulos D, Vilstrup H, Olsen J (1998) Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 28: 921-925
44. Stieber P, Hasholzner U, Bodenmuller H, Nagel D, Sunder-Plassmann L, Dienemann H, Meier W, Fateh-Moghadam A (1993) CYFRA 21-1: a new marker in lung cancer. Cancer 72: 707-713
45. Su WC, Chan KK, Lin XZ, Lin PW, Chow NH, Shin JS, Chen CY, Tsao CJ (1996) A clinical study of 130 patients with biliary tract cancers and periampullary tumors. Oncology 53: 488-493
46. Sugama Y, Kitamura S, Kawai T, Ohkubo A, Hasegawa S, Kuriyama T, Kato H, Fukuoka M, Ohkawa J (1994) Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res 85: 1178-1184
47. Taguchi J, Nakashima O, Tanaka M, Hisaka T, Takazawa T, Kojiro M (1996) A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol 11: 758-764
48. Takada M, Masuda N, Matsuura E, Kusunoki Y, Matui K, Nakagawa K, Yana T, Tuyuguchi I, Oohata I, Fukuoka M (1995) Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br J Cancer 71: 160-165
49. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M (1995) Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 21: 650-655
50. Tomimatsu M, Ishiguro N, Taniai M, Okuda H, Saito A, Obata H, Yamamoto M, Takasaki K, Nakano M (1993) Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer 72: 683-688
51. Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnu L, Zoli M, Grazi GL, Del PP, Di N, Bernardi M (2002) Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 97: 734-744
52. Uenishi T, Hirohashi K, Kubo S, Yamamoto T, Yamazaki O, Kinoshita H (2001) Clinicopathologic factors predicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma. Br J Surg 88: 969-974
53. Uenishi T, Hirohashi K, Shuto T, Yamamoto T, Kubo S, Tanaka H, Ikebe T, Kinoshita H (2000) Surgery for mixed hepatocellular and cholangiocellular carcinoma. Hepatogastroenterology 47: 832-834
54. van der Gaast A, Schoenmakers CH, Kok TC, Bligenberg BG, Cornilie F, Splinter TA (1994) Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. Br J Cancer 69: 525-528
55. Wang YJ, Lee SD, Shyu JK, Lo KJ (1994) Clinical experience in 126 patients with tissue-proved proximal cholangiocarcinoma. J Gastroenterol Hepatol 9: 134-137
56. Wu F, Fujita J, Murota M, Li JQ, Ishida T, Nishioka M, Imaida Y, Kuriyama S (2002) CYFRA 21-1 is released in TNF-alpha-induced apoptosis in the hepatocellular carcinoma cell line HUH-7. Int J Oncol 21: 441-445
57. Yamamoto M, Takasaki K, Nakano M, Saito A (1998) Minute nodular intrahepatic cholangiocarcinoma. Cancer 82: 2145-2149
58. Yamanaka N, Okamoto E, Oriyama T, Fujimoto J, Furukawa K, Tanaka T, Tanaka W, Nishigami T (1995) Clinicopathologic spectrum of resected extraductal mass-forming intrahepatic cholangiocarcinoma. Cancer 76: 2449-2456